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Platelet-derived growth factor A-chain expression in developing and
mature human kidneys and in Wilms' tumor. Regulated expression of
PDGF A-chain may be important in kidney development. We employed
two polyclonal antisera to detect expression of PDGF A-chain in fetal and
normal adult kidneys by immunohistochemistry. Specificity of the antisera
was demonstrated by Western blots of fetal and adult kidneys, demon-
strating monospecific bands at 10 to 15 kD, and by absorption studies with
PDGF-A peptide. PDGF A-chain is uniformly expressed by visceral
glomerular epithelial cells and the epithelial cells of the distal nephron,
including collecting ducts and contiguous urothelium lining the renal
pelvis, in both fetal and adult kidneys. Fetal kidneys also demonstrate
expression of PDGF A-chain at the earliest stages of vesicle formation
from the metanephric blastema; this expression is then only intermittently
detectable in developing glomeruli until differentiation of visceral epithe-
hal cells occurs. Fetal and mature arterial smooth muscle cells, and some
neointimal smooth muscle cells in sclerotic arteries in adult kidneys also
express PDGF A-chain. In situ hybridization with a riboprobe made from
PDGF A-chain cDNA showed close correlation of mRNA expression with
protein immunohistochemistry. PDGF A-chain expression was also iden-
tified in epithelial elements of 5/6 Wilms' tumors studied. These are the
first studies to localize PDGF A-chain expression in human kidney and
suggest sites of activity for PDGF A-chain in development, neoplasia, and
in the renal arterial sclerosis of aging.
Platelet-derived growth factor (PDGF) exists as a dimer com-
posed of two homologous but distinct peptides termed PDGF A
and B chains. These peptides have distinctive functional qualities
and are encoded by genes located on different chromosomes [1,
21. The functional PDGF molecule can exist in each of the three
possible isoforms: PDGF AA, AB, BB. The role of PDGF B-chain
has been extensively studied in glomerular cells in vitro [3—6], in
experimental models of glomerulonephritis [reviewed in 6—8],
and in human renal development and disease [9—12]. The role of
PDGF A-chain in renal disease is not as well known, due largely
to the lack of useful reagents to evaluate expression of this
molecule in normal and diseased states. We have previously
shown by Northern blotting techniques that PDGF A-chain gene
expression is up-regulated in rat glomeruli during the proliferative
phase of mesangial proliferative glomerulonephritis induced by
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administration of anti-Thy-i antibody [13]. Others have shown
that PDGF A-chain gene transcription can be up-regulated in
cultured mesangial cells exposed to phorbol ester, exogenous
PDGF BB homodimer, and a number of peptide mitogens
[14—16]. It is not known if other cell types within the rodent
glomerulus express PDGF A-chain either constitutively or in
response to specific stimuli.
In this study, we report additional characterization of two
commercially available antibodies to PDGF A-chain and the use
of these antibodies to define the expression of PDGF A-chain in
human renal development and mature renal tissue by immunocy-
tochemical methods. We further report the localization of corre-
sponding mRNA production for PDGF A-chain by mature renal
tissue using in situ hybridization techniques. These studies dem-
onstrate PDGF A-chain expression in the visceral epithelial cells
of differentiating fetal human glomeruli, and the persistent ex-
pression of this molecule by these cells in the mature glomerulus.
PDGF A-chain is widely expressed by urothelial epithelium of the
urinary tract both in developing and mature kidneys. This study
also demonstrates the expression of PDGF A-chain by medial
smooth muscle cells of the arterial vasculature in developing and
mature human kidney, and its expression by a sub-population of
intimal smooth muscle cells in the intimal proliferative sclerosing
process characteristic of arterial vessels in aging kidneys. Finally,
we also demonstrate PDGF A-chain expression in epithelial
elements of Wilms' tumors reminiscent of the patterns of expres-
sion identified in normal kidney development.
Methods
Source of tissue
Human fetal kidneys (N = 12), estimated gestational age
ranging from 54 to 122 days, were obtained fresh from tissue
examined after therapeutic abortions. Tissues were fixed in methyl
Carnoy's (methacarn) solution (60% methanol, 30% chloroform,
10% acetic acid) and processed and embedded in paraffin accord-
ing to conventional techniques.
Normal human kidney (N = 21) was obtained fresh from
uninvolved portions of kidneys surgically resected for localized
renal cell carcinoma, or from cadaver donor kidneys unable to be
utilized for transplantation. Portions of these tissues were fixed in
either methacarn or 10% neutral buffered formalin and processed
as above.
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Tissue from Wilms' tumors (N = 6) was obtained fresh after
surgical excision and portions fixed in both methacarn and 10%
neutral buffered formalin. Tissue remaining after all sections
needed for medical diagnosis had been obtained was utilized for
this study. None of the tumors were obtained from patients with
familial occurrence and none were known to occur in concert with
Wilms' tumor associated syndromes.
Antibodies
PDGF A-chain. Anti-PDGF A (Santa Cruz Biotechnology mc,
Santa Cruz, CA, USA) is an affinity-purified rabbit polyclonal
antibody raised against a 30 amino acid peptide corresponding to
the amino terminus of the human PDGF A-chain. The antibody
specifically recognizes human PDGF A-chain under reducing and
non-reducing conditions, and is non-reactive with either reduced
or unreduced PDGF B-chain or unreduced human PDGF-AB.
The second antisera utilized is a rabbit polyclonal protein A
purified anti-human PDGF-AA (Upstate Biotechnology Inc.,
Lake Placid, NY, USA) which specifically recognizes PDGF-AA
homodimer and PDGF-AB heterodimer. The immunogen for this
antisera was purified human recombinant PDGF-AA homodimer
[17], and this antisera neutralizes PDGF-AA and PDGF-AB in a
PDGF stimulation of 3T3 cells bioassay.
Smooth muscle cell markers. Murine monoclonal antibody 1A4
(Dako Corp.) has been characterized by tissue immunohistochem-
istly and Western blotting [18], and has been previously demon-
strated to recognize smooth muscle a-actin in methyl Carnoy's
fixed tissues [19, 20].
Immunohistochemistry
Immunohistochemistry was performed on methyl Carnoy's
fixed, paraffin embedded tissues following a standard avidin-biotin
complex (ABC) method, as previously described [20, 21].
Briefly, sections were deparaffinized in xylene and rehydrated in
graded ethanols. Endogenous peroxidase was blocked by incuba-
tion in 3% hydrogen peroxide and non-specific binding was
blocked by incubation in 10% normal goat serum. The sections
were then incubated overnight with the anti-PDGF-A or anti-
PDGF-AA antisera in a humid chamber at 4°C. Following washes
in PBS, the sections were sequentially incubated with biotinylated
goat-anti-rabbit antisera (Vector Laboratories, Burlingame, CA,
USA), the ABC-Elite avidin reagent (Vector Laboratories) and
finally 3,3'-diaminobenzidine (with nickel chloride enhancement)
as the chromogen. The sections were counterstained with methyl
green, dehydrated and coverslipped.
Double labeling immunocytochemistty
Methyl Carnoy's fixed, paraffin embedded tissues were sec-
tioned and mounted on aminopropylmethoxysilane (APTS)
coated slides. After deparaffinization and rehydration, the slides
were sequentially incubated with the anti-a-smooth muscle actin
antibody; goat anti-mouse IgG-gold (Amersham, Arlington
Heights, IL, USA) diluted in PBS plus 1% BSA and 0.1% gelatin
for one hour at room temperature. Sections were washed, and the
gold was visualized with an IntenSE M silver enhancement kit
(Amersham). The sections were then incubated sequentially with:
(1) rabbit-anti-PDGF A-chain diluted in PBS plus 1% BSA
overnight at 4°C; (2) biotinylated goat-anti-rabbit IgG (Vector
Laboratories); and (3) avidin-biotin-alkaline phosphatase com-
plex (Vector Laboratories). The alkaline phosphatase was devel-
oped with a red substrate kit (Vector Laboratories) and the slides
were counterstained with methyl green. Negative controls in-
cluded substituting absorbed anti-PDGF A-chain antisera (see
below), and substituting normal mouse IgG for the anti-a-smooth
muscle actin.
Antibody absoiption
Microtiter ELISA plates were coated with PDGF-A protein
and PDGF-A control peptide (both from Santa Cruz Biotechnol-
ogy, Inc.) CA) diluted in 50 m carbonate buffer, pH 9.0, at
concentrations ranging from 1 xg/ml to 100 Wml. After over-
night incubation at 4°C, the antigen solution was removed and the
plates were blocked with PBS containing 1% BSA and 0.02%
sodium azide for two hours at room temperature. The plates were
then washed with PBS and allowed to air dry. Rabbit anti-
PDGF-A (Santa Cruz Biotechnology, Inc.) or rabbit anti-
PDGF-AA (UBI) diluted 1/50 in PBS plus 2% BSA was added
and the plates were incubated overnight at 4°C. The supernatant
was removed from the wells and used as the absorbed primary
antibody in a standard ABC immunohistochemistry procedure
and was also used as a control in the Western blotting experiments
detailed below. Positive controls (that is, repetition of the absorp-
tion procedure without antigen-specific absorption of the anti-
sera) were done by using carbonate buffer only to coat the
microtiter wells. This control antisera was used in procedures
identical to those of the primary unabsorbed and absorbed
antisera, and gave results similar to that of the original unmanipu-
lated antisera (data not shown).
Western blotting
Homogenates of normal adult and fetal kidneys were electro-
phoresed on a 15% SDS polyacrylamide gel and then blotted onto
nitrocellulose membranes. The blots were blocked with 5% BSA
in PBS for one hour at 37°C and then incubated with anti-
PDGF-A (Santa Cruz Biotechnology, Inc.) or anti-PDGF-AA
(UBI) diluted 1/250 in 10 mrvi PBS containing 0.1% BSA and 10
m sodium azide (PBS-BSA) for two hours at room temperature.
After washing, the blots were incubated with a 1/100 dilution of
gold conjugated goat-anti-rabbit (Amersham Corp.) for two
hours. The gold signal was then enhanced by incubation in
IntenSE BL (Amersham Corp.). In control experiments, reduced
PDGF-AA protein (Santa Cruz Biotechnology, Inc.) and recom-
binant human PDGF-AA (UBI) and recombinant human
PDGF-BB (UBI) were used to demonstrate specificity of the
antisera. As a negative control, the primary antibody was replaced
by normal rabbit IgG at an equivalent dilution.
Molecular probe
A 1280 bp human PDGF A-chain cDNA [22] was subcloned
into SP64 vector. This probe was a gift of Dr. J.N. Wilcox, Emory
University. The construct was linearized and transcribed into an
antisense riboprobe using reagents obtained from Promega Biotec
(Madison, WI, USA), except 35S-UTP, which was obtained from
New England Nuclear (Boston, MA, USA). The transcription
reaction mixture contained 1 xg of PDGF A cDNA (either sense
or antisense), 250 xCi 35S-UTP (1,100 to 1,300 Ci/mmol), 500 jxM
each of ATP, CTP, and GTP, 40 U RNasin, 10 mr'i dithiothreitol,
40 mM Tris, and 10 U of either SP6 or T7 polymerase. After 75
minutes at 37°C, the DNA was digested by adding 1 U DNase
(Promega) and incubation at 37°C for an additional 15 minutes.
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Free nucleotides were then separated using a Sephadex G-50
column. Specific activity of the probes ranged from 5 to 30 x i07
cpm/mg. Probes were used immediately.
In situ hybridization
Adult kidney tissue which had been fixed in 10% formalin and
embedded in paraffin was deparaffinized following standard pro-
tocol. The sections were washed with 0.5>< standard saline citrate
(SSC) (IX SSC = 150 mrvt NaCl, 15 m Na citrate, pH 7.0) and
digested with proteinase K (1 xg/mL) (Sigma) in RNase A
(Promega) buffer for 40 minutes at 37°C. Several 0.5x SSC
washes were followed by prehybridization for two hours in 50 .tl
of prehybridization buffer (0.3 M NaCl, 20 mrvt Tris pH 8.0, 5 mM
EDTA, 1>< Denhardt's solution, 10% dextran sulfate, 10 mvt
DTT). The hybridizations were started by adding 500,000 cpm of
35S-labeled riboprobe in 50 of prehybridization buffer and
allowed to proceed overnight at 50°C. After hybridization, sec-
tions were washed with 0.5X SSC, treated with RNase A (20
itgIm1, 30 mm room temperature), washed in 2X SSC (2 X 2 mm),
followed by three high stringency washes in 0.1X SSC/Tween 20
(Sigma) at 37°C, followed by several 2x SSC washes. After the
tissue was air dried, it was dipped in NTB2 nuclear emulsion
(Kodak) and exposed in the dark at 4°C for four weeks. After
developing, the sections were counterstained with hematoxylin
and eosin, dehydrated, mounted and viewed.
Results
Immunohistochemistiy
Two developmental stage-specific patterns of PDGF A-chain
expression in developing nephrons were identified. PDGF A-
chain could be first identified at the earliest stage of conversion of
metanephric blastema into an epithelial vesicle, when this differ-
entiating epithelium is still in close contact with the inductive
differentiating stimulus, the ureteric bud (Fig. 1). There is no
expression of PDGF A-chain by the adjacent blastema, ureteric
bud, or interstitial tissue. As glomerular development proceeds
through subsequent comma and S-shape stages, as they have been
characterized by Saxén, Ekblom, and others [23—25], PDGF
A-chain expression often becomes undetectable, although focal,
intermittent expression by the epithelial cells comprising these
primitive glomeruli is present. This variability was encountered
not only between different kidney samples, but between glomer-
ular structures of apparently identical morphologic development
within the same tissue sections (Fig. 1B). In the last stages of
glomerular development, PDGF A-chain is uniformly expressed
by the visceral epithelial cells overlying glomerular capillaries
(Fig. 1 C, D). The staining pattern is cytoplasmic, and appears to
be of uniform intensity for glomeruli at all levels of maturation
within developing kidneys (that is, superficial glomeruli as well as
those near the cortico-medullary junction) once visceral epithelial
cell differentiation has occurred. A minority of these differenti-
ated glomeruli also show diffuse cytoplasmic expression of PDGF
A-chain by parietal epithelial cells. Expression of PDGF A-chain
by mesangial cells or endothelial cells is not detectable. Extraglo-
merular structures exhibiting widespread expression of PDGF
A-chain included the urothelial lining of the ureter and renal
pelvis, collecting duct epithelium in contiguity to the urothelium,
and the smooth muscle cell layers of the developing renal arterial
vasculature (Fig. 1 A, E).
The normal adult kidneys demonstrated persistence of patterns
of PDGF A-chain expression exhibited late in renal development.
Specifically, there is widespread expression by glomerular visceral
epithelial cells and some parietal epithelial cells, but not other
glomerular structures (Fig. 2A), widespread expression by collect-
ing ducts and the urothelium lining the lower urinary tract (Fig.
2B), and diffuse expression by medial smooth muscle cells of the
renal arterial tree (Fig. 2 A, C, D). In addition, many of the renal
arteries sampled exhibited variable, most often mild to moderate,
degrees of intimal sclerosis characteristic of aging kidneys. The
majority of neointimal smooth muscle cells (shown by labeling
with the a-smooth muscle actin antibody) present in these scle-
rosing arteries also exhibited prominent expression of PDGF
A-chain (Fig. 2 C, D). PDGF A-chain expression by medial
smooth muscle cells in these arteries was indistinguishable from
that seen in arteries without prominent neointimal sclerosis.
The Wilms' tumor specimens exhibited the varied histopatho-
logic features characteristic of these neoplasms, including blast-
emal, epithelial, and mesenchymal elements. All but one of these
tumors exhibited focal expression of PDGF A-chain. PDGF
A-chain expression was confined to more differentiated epithelial
elements within these tumors, whereas neoplastic blastemal and
mesenchymal structures had no detectable expression (Fig. 2E).
Epithelial elements expressing PDGF A-chain often, but not
invariably, assumed a tubular configuration; rarely, the PDGF
A-chain expression in such structures appeared to be confined to
the luminal surface, implying a degree of cell polarity. As expected
from studies of normal kidneys, smooth muscle cells and/or
pericytes comprising the non-neoplastic, infiltrating tumor vascu-
lature also expressed PDGF A-chain.
No significant differences in staining patterns were identified
between either of the two primary antisera utilized, although a
stronger signal was obtained with the antisera raised against the
30 amino acid terminus of PDGF A-chain monomer. No specific
cellular staining was seen with substitution of control rabbit IgG
or PBS for the primary antibody. Staining patterns were uniform
in both adult and fetal kidneys except for the variability in
detectable expression of PDGF A-chain by early differentiating
Fig. 1. Expression of PDGFA-chain in developing kidneys. A. Low power photomicrograph of 59 day gestational age kidney showing expression of PDGF
A-chain in developing glomerular structures, muscular arteries (arrows) and urothelium lining the renal pelvis (arrowheads). There is no expression in
the rim of metanephric blastema (b) at the outer cortex of the kidney, or in interstitial cells. B. Same kidney as A. PDGF A-chain is expressed by
epithelia of early differentiating structures (S and comma shaped/folded nephrons) but not by adjacent undifferentiated blastema. C. Differentiated fetal
glomeruli uniformly demonstrate PDGF A-chain expression by visceral epithelial cells and irregularly by parietal epithelial cells lining Bowman's
capsules. D. High magnification of a fetal glomerulus demonstrating PDGF A-chain expression in visceral epithelial cells. E. PDGF A-chain expression
by smooth muscle cells of arteries (arrows) in a fetal kidney. F. Low power view of PDGF A-chain expression in fetal kidney of 81 days gestational age,
demonstrating patterns described in A-E. G. Adjacent tissue section to that shown in F reacted with absorbed antisera. There is complete abolition of
staining, providing strong evidence of antibody specificity.
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vesicular and glomerular structures as indicated above. Replica-
tion of the immunohistochemical procedures with the absorbed
antisera removed the specific staining of arterial smooth muscle
cells, urothelium, and glomerular epithelial cells (Fig. 1 F, G).
In situ hybridization
In situ hybridization studies of fetal kidneys could not be
performed due to degradation of the mRNA transcripts in these
tissues. Studies of the adult kidneys showed a pattern of PDGF
A-chain mRNA production corresponding to the patterns of
protein expression described above. Hybridization signal was
strongest overlying the smooth muscle cells comprising the media
of arteries (Fig. 2F). Discrete signals were also identified in some
neointimal smooth muscle cells, in some glomerular visceral
epithelial cells and, rarely, parietal epithelial cells (Fig. 2G).
While the distribution of mRNA expression revealed no discrep-
ancies with the immunolabeling results (that is, no cell types
appeared to produce PDGF A-chain mRNA that did not express
identifiable PDGF A-chain protein), there was much less unifor-
mity of mRNA production by positive cell types within each
individual tissue section when assessed by our hybridization
techniques as compared to the immunolabeling results. This may
not represent a meaningful biological difference as hybridization
incubation times were relatively short and other technical details
(such as time of fixation after surgical removal of the specimen)
for which hybridization studies are more sensitive than protein
immunocytochemistry could not always be rigorously controlled.
All positive hybridization results were obtained with use of the
"antisense" strand probe; concomitant procedures utilizing the
"sense" strand probe were uniformly negative (data not shown).
Western blotting
Both the anti-PDGF-A and anti-PDGF-AA antisera demon-
strated discrete bands corresponding to proteins of 10 to 15 kD
which correspond to the size of the PDGF A-chain monomer as
indicated by simultaneous blotting of a control preparation of
purified PDGF-AA (Fig. 3). Identical bands were found in both
fetal and mature kidneys. In separate blotting experiments, both
antisera recognized reduced and unreduced recombinant human
PDGF-AA protein, with discrete bands at 14 to 18 kD and 30 to
32 kD, respectively. The antisera did not recognize reduced or
unreduced PDGF-BB (data not shown). In separate blotting
experiments, the identification of the 10 to 15 kD band could be
abolished by the use of the antiserum pre-absorbed with PDGF-A
peptide (data not shown).
Discussion
The potential significance of PDGF A-chain in renal develop-
ment is suggested by studies identifying a Wilms' tumor gene and
its protein product WT1 [26]. One of the few known activities of
the WT1 protein is that it has been shown to bind and repress the
transcription activating sequence of the PDGF A-chain gene
[27—29]. Mutations in this gene, which lead to the development of
Wilms' tumor, might then be expected to lead to increased
expression of PDGF A-chain, possibly in the Wilms' tumor itself,
but also possibly within the non-tumorous renal parenchyma. The
effects of such expression are not predictable, given how little is
known of the function or sites of expression of PDGF A-chain and
its receptor in either kidney development or normal physiologic
activity.
This study demonstrates expression of PDGF A-chain in
Wilms' tumors, albeit in a pattern restricted to tumor elements
demonstrating epithelial and most often tubular differentiation.
Those portions of Wilms' tumors exhibiting features more like
undifferentiated blastema or primitive mesenchyme (in distinction
from the non-neoplastic mesenchymal structures comprising the
infiltrating tumor vasculature) were never found to express PDGF
A-chain. Wilms' tumors typically demonstrate composite histo-
logic features comprising blastema and mesenchymal elements as
well as more differentiated epithelial elements [30]; the signifi-
cance of PDGF A-chain expression by only one of these elements
is of unknown clinical or biologic significance. However, this
finding in Wilms' tumors does correspond to the pattern of PDGF
A-chain expression by vesicular structures at the earliest stage of
epithelial differentiation from the blastema and by tubular struc-
tures of the distal nephron in developing metanephric kidneys;
tumor expression of PDGF A-chain may then be both a function
and potential histologic marker of tumor differentiation. The
differentiating elements of these tumors in this instance appear to
maintain fidelity of growth factor expression with normal renal
development.
Our studies also demonstrate expression of PDGF A-chain in
the developing metanephric kidney in humans (Table 1). They
show expression that is predominantly localized to differentiating
visceral epithelial cells, collecting duct structures and the contig-
uous urothelial lining of lower urinary tract structures such as
renal pelvis and ureter, and the smooth muscle cells of the arterial
vasculature, These relatively differentiated structures bear no
obvious relation to the metanephric blastema from which Wilms'
tumors arise. However, as noted above, PDGF A-chain is also
expressed in a restricted manner to vesicular structures which
Fig. 2. A. Adult normal human glomerulus showing persistent expression of PDGF A-chain in visceral epithelial cells, parietal epithelial cells, and the
smooth muscle cells of a hilar arteriole. B. Adult normal human kidney shows persistent, widespread expression of PDGF A-chain by urothelium lining
the renal pelvis (arrow) as well as by the contiguous epithelium of the renal collecting ducts. C. Arcuate artery from adult human kidney with intimal
sclerosis. PDGF A-chain is expressed by smooth muscle cells comprising both the vessel media and intima (i). Several smaller arteries also demonstrate
PDGF A-chain expression by medial smooth muscle cells. D. Double immunolabeling of an intrarenal artery from an adult human kidney also
demonstrating intimal (i) sclerosis. PDGF A-chain expression by smooth muscle cells is identified by red alkaline phosphatase label, while the smooth
muscle cell identity of intimal and medial cells is confirmed by co-localization of a black immunogold label for a-smooth muscle actin. E. Wilms' tumor.
There is focal expression of PDGF A-chain by portions of the tumor exhibiting epithelial differentiation, while less well differentiated (blastemal)
elements do not express detectable levels of this peptide. F. In situ hybridization of adult human kidney, with PDGF A-chain mRNA expression
demonstrable in smooth muscle cells of renal arterial structures, in accordance with immunohistochemical results. Adventitia and adjacent matrix cells
show no expression. G. Same kidney as F, with glomerulus showing PDGF A-chain mRNA expression which can generally be localized to visceral
epithelial cells at periphery (arrows) and central portions of glomerular tuft.
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Fig. 3. Western blots utilizing each of the PDGFA-chain antisera employed in this study, reacted with tissue obtained from adult (lanes 1—3) and fetal (lane
4) human kidneys. Lane 5 contains PDGF A-chain peptide. Monospecific bands are obtained with the anti-PDGF-AA antisera in A, and with antisera
directed against the 30 amino acid terminus of PDGF A-chain in B. Higher molecular weight bands recognized in lane S indicate likely dimerization
of the peptide.
comprise the earliest stages of differentiation of the nephron from
the blastema. This localization of PDGF A-chain suggests the
possibility that PDGF A-chain could play a role critical in the
early events in the differentiating metanephric kidney. Of partic-
ular note is that this pattern of PDGF A-chain expression in early
and differentiated glomerular epithelial structures is similar, if not
identical, to that reported for the WT1 gene product in developing
human kidneys [31, 32]. That PDGF A-chain expression as well as
that of a protein that represses PDGF A-chain expression should
co-localize to the same cell types presents a paradox that is
currently unexplainable. However, this finding does indicate that
expression of the WT-1 gene product alone is insufficient to
repress PDGF A-chain expression by at least some cell types of
the developing kidney. Alternatively, it is possible that the WT1
protein may also function as a gene activator under conditions
that still need to be defined [29]. We cannot exclude the possibility
that even earlier in development, a further program(s) of PDGF
A-chain expression and/or suppression are required for initial
formation of metanephric kidney structures, but that such pro-
grams are no longer essential or detectable in the process of
conversion of metanephric blastema to differentiated nephronal
structures which was a focus for this study. This possibility is
supported by studies in mice using knockout techniques which
show that deletion of the WT1 gene results in failure to develop
differentiated metanephric structures concomitant with absence
of the ureteric bud which induces such differentiation [33].
Additional considerations of these findings in developing and
mature kidneys are in order. PDGF B-chain has previously been
localized to developing nephronal epithelial structures, at a stage
slightly later than that of PDGF A-chain expression (Table 1) [9].
Co-localization of PDGF /3 receptor (which binds only the PDGF
B-chain isoform) to the metanephric blastema and interstitial
tissues suggested local paracrine interactions by which PDGF
B-chain activity could promote further glomerular differentiation
[9]. In the absence of reagents that would allow localization of the
PDGF a receptor, which binds the PDGF A-chain isoform, we are
unable to define the significance of PDGF A-chain expression at
these stages of development to a similar degree. One possibility,
suggested by the known ability of PDGF A-chain to stimulate
proliferation and migration of vascular smooth muscle cells, is
that PDGF A-chain may promote the local migration of intersti-
tial vascular elements into the glomerulus in the process of
establishing the glomerular vascular architecture [2, 34, 35].
Secondly, as glomerular differentiation proceeds, there is clear
divergence of the sites of PDGF-A and B chain production.
PDGF B-chain, and the PDGF13 receptor which binds only PDGF
B-chain, are produced by mesangial cells in health and disease in
both humans and rodents [6, 7, 10, 12, 13, 36], although in the rat
injured visceral epithelial cells also have been shown to produce
PDGF B-chain [37]. Once the developing human glomerular tuft
has differentiated, PDGF A-chain production appears confined to
visceral epithelial cells throughout the maturation process and
into adulthood. Other growth factors with a similar localization in
the human glomerulus are vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF) [38—40]. It is
known that there is a limited homology between the genes
encoding VEGF and PDGF [41, 42], but other structural, inter-
active, or molecular relationships among these three peptide
growth factors have not been identified. Although VEGF, bFGF,
and PDGF do share mitogenic, angiogenic and chemotactic
properties to a varying degree [2, 41—45], it is not clear how such
properties may contribute to visceral epithelial cell function and
injury.
Thirdly, PDGF A-chain demonstrates widespread expression by
the smooth muscle cells of the renal vasculature, including smooth
muscle cells in the neointima of arteries demonstrating intimal
sclerosis. PDGF A-chain protein and mRNA has been localized
previously to human atherosclerotic plaques [35, 46, 47], and
up-regulated expression of this molecule has also been demon-
strated in the neointima of rat arteries subjected to balloon
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Table 1. Phenotypic characterization of stages of glomerulogenesis in
human fetal kidney
Early
glomerular
differentiation
Metanephric
blastema Vesicle
(comma,
S-stage)
Differentiated
glomerulus
• PDGF B-chain — +1— — Mesangium
• PDGFRI3 + — Mesangium
• PDGF A-chain — focal + Visceral epithelial
cell
• WT1 — focal + Visceral epithelial
cell
Expression of members of the PDGF system and the potentially
regulatory protein WT1 during human glomerulogenesis. Data Ofl PDGF
B-chain and PDGFRI3 are from [9]; data on WT1 expression are from
[31, 32].
catheter injury [34]. Based on the sequence of pathologic events
occurring in experimental balloon catheter injury and on studies
of vascular smooth muscle cells in vitro, evidence has accumulated
that PDGF A-chain may function as a smooth muscle cell mitogen
and promoter of vascular smooth muscle cell migration. In this
study, the arterial localization of PDGF A-chain provides the first
direct demonstration of the potential of PDGF A-chain to
participate in human renal vascular injury. The identification of
PDGF A-chain in neointimal smooth muscle cells in particular
suggests the potential for both paracrine and autocrine activity
involving these mesenchymal cells within the vessel neointima, as
well as the potential to stimulate the neighboring smooth muscle
cells of the arterial vessel media to replicate or migrate and hence
promote further neointimal expansion. It has even been suggested
that PDGF A-chain may have non-mitogenic trophic functions
that are otherwise unspecified but nonetheless important in the
maintenance of arterial structures [47]. The apparently constitu-
tive expression of PDGF A-chain mRNA and protein by medial
smooth muscle cells in both developing and mature arteries is
evidence for such a trophic function in renal arteries. Since
virtually nothing is known of the processes which cause the renal
arterial sclerosis that is a hallmark of renal aging, nor of those
causing sclerosis as a consequence of more discreet forms of
vascular injury, we are unable to more specifically identify the
specific functional roles of PDGF A-chain in these processes as
yet. However, in situ identification of expression of molecules at
both the transcriptional and protein levels that could mediate such
processes is an initial approach towards understanding the patho-
genetic basis of human renovascular disease. Some evidence in
support of a role for PDGF A-chain in such processes is provided
in our recent study of allograft kidneys demonstrating widespread
expression of PDGF A-chain by the neointimal cells of arteries
demonstrating chronic vascular rejection in these kidneys [48].
In summary, our studies indicate regulated expression of PDGF
A-chain in developing kidney glomerular epithelial cells, tubules,
and blood vessels and persistence of these patterns into adult-
hood. However, they do not identify the role of PDGF A-chain in
human kidney development or answer the question of whether the
PDGF A-chain expression observed is essential for normal kidney
maturation and function. The critical role for PDGF B-chain in
this process has recently been demonstrated in the PDGF B-chain
knockout mouse which revealed that PDGF B-chain is required
for normal development of the glomerular mesangium [49]; the
importance of PDGF A-chain may be determined by a similar
experimental approach. Knowledge about the sites of activity for
PDGF A-chain within the kidney awaits better localization of its
receptor. It has been reported recently that in the adult kidney
PDGFa receptor co-localizes in a distribution similar to PDGF 13
receptor [12]; however, none of this was illustrated and we remain
cautious in our understanding of the distribution of PDGF a
receptor. Some indication of a role for PDGF A-chain in the
pathogenesis of renal vascular disease is already provided by
demonstration of its expression in atherosclerosis [35, 47], renal
arteriosclerosis, and renal allograft rejection [48]. Finally, we have
identified a pattern of glomerular expression of PDGF A-chain
similar to that of the Wilms' tumor gene product and further
identified PDGF A-chain expression in a portion of Wilms'
tumors, adding to the evidence associating these molecules in the
processes of renal development and neoplasia.
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